Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 30

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 30
---
 leading academic institutions and CROs. In building and developing our product portfolio, we believe that accessing external                 
 innovation, expertise and technology through collaboration with leading academic institutions and CROs is a vital and cost-efficient              
 strategy. We have established strong relationships with leading academic institutions around the world and expect to continue to strengthen       
 our collaborations by, for example, seeking to provide their affiliated Principal Investigators resources through sponsorship to conduct          
 further research in specialty fields of interest and association with personnel connected to our current project companies, in exchange           
 for obtaining for the Company the first right to negotiate for an exclusive license to any resulting innovations. In addition, we have            
 entered and will continue to actively source arrangements with pharmaceutical companies, in most cases in roles as contract research              
 organizations, to streamline the development of our projects. This may include outsourcing part of the preclinical, clinical studies              
 and clinical supplies manufacturing to externally accredited cGLP, cGMP and cGCP standard contract research organizations or laboratories         
 in order to attain the required studies for submission to the regulatory authorities as part of the clinical development plan. (See “Arrangements 
 with Other Parties”)                                                                                                                              |

| ● | Obtaining                                                                                                                            
 and leveraging government grants to fund project development. Governments across the world pay close attention to the development    
 of the biotechnology sector and provide support and funding. We intend to seek government support from the governments in the United 
 States, the United Kingdom, Hong Kong, Singapore and elsewhere for our product development and to facilitate the development of some 
 of our projects.                                                                                                                     |

Aptorum’s corporate strategy has been to license cutting edge medical technologies that we deem to have substantial potential value. DiamiR’s liquid biopsy for the mild cognitively impaired patients fits with the technologies that we are looking for as it provides minimally invasive and early diagnosis of a disease that will impact an ever-growing aging population.

<div align='center'>9</div>

Arrangements with Other Parties Historically, we licensed early-stage programs from universities and further development work is mainly conducted in universities via SRAs. As for the development of our drug candidates, our R&D Center conducts part of the CMC work. However, since our current facilities are not cGMP, cGLP or cGCP qualified, we will have to rely on CROs to conduct that type of work, if and when our drug candidates reach the level of development that requires such qualification. Company’s Securities Our authorized share capital is divided into Class A Ordinary Shares and